




PHARMACEUTICAL 2022

Q BioMed Inc.
Rank 461 of 466





PHARMACEUTICAL 2022

Q BioMed Inc.
Rank 461 of 466

The relative strengths and weaknesses of Q BioMed Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Q BioMed Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 318% points. The greatest weakness of Q BioMed Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 394% points.

The company's Economic Capital Ratio, given in the ranking table, is -517%, being 595% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	459
Cost of Goods Sold	247
Intangible Assets	350
Liabilities, Current	5,495
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	852
Other Liabilities	0
Other Net Income	0
Other Revenues	196
Property and Equipment	0
Research and Development	1,074
Selling, General and Administrative Expense	6,263

Output Variable	Value in 1000 USD
Assets	809
Liabilities	5,495
Expenses	8,436
Revenues	196
Stockholders Equity	-4,685
Net Income	-8,241
Comprehensive Net Income	-8,241
Economic Capital Ratio	-517%